Method for treating muscle-invasive bladder cancer, containing S100A9 and EGFR inhibitors and cisplatin as active ingredients
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 27, 2017
Grant Date -
Jan 21, 2016
app pub date -
Jun 19, 2015
filing date -
Dec 20, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a method for predicting the probability of muscle-invasive bladder cancer (MIBC) recurrence or metastasis, a method for providing information on a personalized medicine of MIBC, and a pharmaceutical composition for treating MIBC, containing S100A9 and EGFR inhibitors and cisplatin as active ingredients. According to the present invention, it is possible to accurately predict a prognosis after chemotherapy of an MIBC patient, to provide information on cisplatin sensitivity in the provision of a personalized medicine for chemotherapy of an MIBC patient, and to increase the cisplatin sensitivity of an MIBC patient by concomitantly administering S100A9 and EGFR inhibitors together with a conventional cisplatin.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully